These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 17409894)

  • 1. Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy.
    Bruzzi JF; Truong M; Zinner R; Erasmus JJ; Sabloff B; Munden R
    J Thorac Oncol; 2006 Jun; 1(5):425-9. PubMed ID: 17409894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
    Weber WA; Petersen V; Schmidt B; Tyndale-Hines L; Link T; Peschel C; Schwaiger M
    J Clin Oncol; 2003 Jul; 21(14):2651-7. PubMed ID: 12860940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
    Geiger GA; Kim MB; Xanthopoulos EP; Pryma DA; Grover S; Plastaras JP; Langer CJ; Simone CB; Rengan R
    Clin Lung Cancer; 2014 Jan; 15(1):79-85. PubMed ID: 24238934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
    Cerfolio RJ; Bryant AS
    Ann Thorac Surg; 2007 Oct; 84(4):1092-7. PubMed ID: 17888953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study.
    De Leyn P; Stroobants S; De Wever W; Lerut T; Coosemans W; Decker G; Nafteux P; Van Raemdonck D; Mortelmans L; Nackaerts K; Vansteenkiste J
    J Clin Oncol; 2006 Jul; 24(21):3333-9. PubMed ID: 16849747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing response to treatment in non--small-cell lung cancer: role of tumor volume evaluated by computed tomography.
    Knollmann FD; Kumthekar R; Fetzer D; Socinski MA
    Clin Lung Cancer; 2014 Mar; 15(2):103-9. PubMed ID: 24361250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer.
    Kunst PW; Lee P; Paul MA; Senan S; Smit EF
    J Thorac Oncol; 2007 Oct; 2(10):912-5. PubMed ID: 17909353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
    Zhao SJ; Wu N; Zheng R; Liu Y; Zhang WJ; Liang Y; Zhang H; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):754-7. PubMed ID: 24378097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and 18F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy: A Mono-institutional Pilot Experience.
    Genestreti G; Burgio MA; Matteucci F; Piciucchi S; Scarpi E; Monti M; Bucchi L; Parisi E; Crociani L; Gurioli C; Poletti V; Gavelli G
    Technol Cancer Res Treat; 2015 Dec; 14(6):721-7. PubMed ID: 24945370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
    J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men.
    Cerfolio RJ; Bryant AS; Scott E; Sharma M; Robert F; Spencer SA; Garver RI
    Chest; 2006 Dec; 130(6):1796-802. PubMed ID: 17166999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid disease progression with delay in treatment of non-small-cell lung cancer.
    Mohammed N; Kestin LL; Grills IS; Battu M; Fitch DL; Wong CY; Margolis JH; Chmielewski GW; Welsh RJ
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):466-72. PubMed ID: 20471184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
    J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mediastinal lymph node staging by means of positron emission tomography is less sensitive in elderly patients with non-small-cell lung cancer.
    Al-Sarraf N; Gately K; Lucey J; Wilson L; McGovern E; Young V
    Clin Lung Cancer; 2008 Jan; 9(1):39-43. PubMed ID: 18282357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucose-positron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers.
    Bryant AS; Cerfolio RJ
    J Thorac Cardiovasc Surg; 2006 Dec; 132(6):1363-8. PubMed ID: 17140957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
    Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging.
    Antoch G; Stattaus J; Nemat AT; Marnitz S; Beyer T; Kuehl H; Bockisch A; Debatin JF; Freudenberg LS
    Radiology; 2003 Nov; 229(2):526-33. PubMed ID: 14512512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.